Montelukast (dicyclohexylamine)

Montelukast (MK0476) dicyclohexylamine is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1) . Montelukast dicyclohexylamine can be used for the reseach of asthma and liver injury. Montelukast dicyclohexylamine also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast dicyclohexylamine decreases eosinophil infiltration into the asthmatic airways. Montelukast dicyclohexylamine can also be used for COVID-19 research[1][2][3][4].

Product Specifications

CAS Number

[577953-88-9]

Product Name Alternative

MK0476 (dicyclohexylamine)

UNSPSC

12352005

Hazard Statement

H410

Target

Leukotriene Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-anti-virus

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/montelukast-dicyclohexylamine.html

Solubility

10 mM in DMSO

Smiles

CC(C)(O)C(C=CC=C1)=C1CC[C@H](C2=CC(/C=C/C3=NC4=C(C=CC(Cl)=C4)C=C3)=CC=C2)SCC5(CC5)CC(O)=O.C6(CCCCC6)NC7CCCCC7

Molecular Formula

C47H59ClN2O3S

Molecular Weight

767.50

Precautions

P273-P391-P501

References & Citations

[1]Pu S, et, al. Montelukast Prevents Mice Against Acetaminophen-Induced Liver Injury. Front Pharmacol. 2019 Sep 18; 10:1070.|[2]William RHJ, et, al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med. 2002 Jan 1; 165 (1) : 108-16.|[3]Langlois A, et al. Montelukast regulates eosinophil protease activity through a leukotriene-independent mechanism. J Allergy Clin Immunol. 2006;118 (1) :113-119.|[4]Khan AR, et al. Montelukast in hospitalized patients diagnosed with COVID-19. J Asthma. 2022 Apr;59 (4) :780-786.